CR-8020
Based on 1 Customer Validation
CR-8020 is a broadly neutralizing antibody targeting the stem region of influenza A virus hemagglutinin (HA), with IC50 values of 0.06 nM or 3.36 nM. CR-8020 mediates antibody-dependent cellular cytotoxicity by activating Fcγ receptors. CR-8020 blocks viral fusion and entry. CR-8020 protects mice from lethal influenza A virus challenge. CR-8020 can be used in research related to influenza A virus infections (H3N2 and H7N9).
For research use only. We do not sell to patients.
- Purity : 95%
- CAS No.: 1422526-93-9
- Molecular Weight:146.434 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
[1]|
Influenza hemagglutinin (HA) |
In Vitro
CR-8020 (0.0001-100 mg/mL) binds with high affinity to H3N2 HA from the A/Wyoming/3/2003 strain (IC50 0.06 nM) and H3N2 HA from the A/Brisbane/10/2007 strain (IC50 3.36 nM), but shows negligible binding to H7N9 HA from the A/Shanghai/02/2013 strain[1].
Most epitope residues of H3N2 and H7N9 HA targeted by CR-8020 are susceptible to sequence drift and host selection pressure, with multiple predicted single-base escape mutations; among these, the D19N escape mutation is present in a circulating H7N9 strain[1].
CR-8020 potently neutralizes and binds to group 2 influenza A virus strains by targeting a highly conserved HA epitope[2].
CR-8020 (1-10000 ng/mL; 6 h) mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in H3N2-infected A549 cells via activation of FcγRIIIa, but its potency is approximately 10-fold lower than that of antibodies targeting the interface of influenza HA trimers[1].
The ternary complexes HA-CR8020-FcγRIIa and HA-CR8020-FcγRIIIa formed by CR-8020 are subject to steric hindrance from viral or cell membranes, which limits the ability of CR8020 to activate FcγRIIa and FcγRIIIa[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:unspecified strain[2]
-
Dosage:3 mg/kg
-
Administration:i.n.; every 24 hours; 7 days
-
Result:Conferred protection against lethal challenge of both mouse-adapted H3N2 and H7N9 viruses.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1422526-93-9
-
Appearance Liquid
-
Molecular Weight 146.434 kDa
-
Color Colorless to light yellow
-
SMILES
[CR8020]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Tharakaraman K, et al. Broadly neutralizing influenza hemagglutinin stem-specific antibody CR8020 targets residues that are prone to escape due to host selection pressure. Cell host & microbe. 2014 May 14;15(5):644-51. [Content Brief]
[2]. Zeng LY, et al. Investigational hemagglutinin-targeted influenza virus inhibitors. Expert opinion on investigational drugs. 2017 Jan;26(1):63-73. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)